ValuEngine upgraded shares of Brainstorm Cell Therapeutics (NASDAQ:BCLI) from a sell rating to a hold rating in a research report sent to investors on Tuesday morning.
Separately, Maxim Group set a $9.00 target price on shares of Brainstorm Cell Therapeutics and gave the company a buy rating in a research report on Thursday, March 8th.
Brainstorm Cell Therapeutics (BCLI) opened at $3.64 on Tuesday. The company has a market cap of $71.81, a P/E ratio of -11.74 and a beta of 1.38. Brainstorm Cell Therapeutics has a 12-month low of $2.88 and a 12-month high of $5.18.
Large investors have recently modified their holdings of the company. Clearline Capital LP acquired a new position in shares of Brainstorm Cell Therapeutics in the 4th quarter valued at approximately $208,000. Deutsche Bank AG increased its position in Brainstorm Cell Therapeutics by 330.0% during the 4th quarter. Deutsche Bank AG now owns 98,590 shares of the biotechnology company’s stock worth $386,000 after purchasing an additional 75,664 shares in the last quarter. Renaissance Technologies LLC increased its position in Brainstorm Cell Therapeutics by 396.9% during the 4th quarter. Renaissance Technologies LLC now owns 114,550 shares of the biotechnology company’s stock worth $449,000 after purchasing an additional 91,495 shares in the last quarter. Finally, Vanguard Group Inc. increased its position in Brainstorm Cell Therapeutics by 2.8% during the 2nd quarter. Vanguard Group Inc. now owns 657,101 shares of the biotechnology company’s stock worth $2,733,000 after purchasing an additional 17,657 shares in the last quarter. Institutional investors own 9.72% of the company’s stock.
Brainstorm Cell Therapeutics Company Profile
Brainstorm Cell Therapeutics Inc is a biotechnology company. The Company is engaged in developing adult stem cell therapies for debilitating neurodegenerative disorders, such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig’s disease), Multiple Sclerosis (MS) and Parkinson’s disease (PD), among others.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Brainstorm Cell Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Brainstorm Cell Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.